Novo Nordisk A/S : Share repurchase programme

company announcement

Novo Nordisk A/S - Share repurchase programme Bagsværd, Denmark, 24 November 2014 - On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning

30 January 2014.
Under the programme initiated 30 October 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 30 October 2014 to 28 January
2015.
Since the announcement as of 17 November 2014, the following transactions have been made under the programme:

Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 2,602,000 684,293,175

17 November 2014 215,000 259.19 55,725,098

18 November 2014 215,000 260.89 56,092,318

19 November 2014 300,000 264.92 79,476,570

20 November 2014 285,000 263.49 75,093,738

21 November 2014 270,000 265.82 71,772,129

Accumulated under the programme 3,887,000 1,022,453,027

With the transactions stated above, Novo Nordisk owns a total of 51,371,153 B shares of DKK 0.20, corresponding to 1.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 71 / 2014

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 21 November 2014, Novo Nordisk has repurchased a total of 48,910,995 B shares equal to a transaction value of DKK
12,226,828,243.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately

41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's

B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:
Anne Margrethe Hauge	+45 3079 3450	amhg@novonordisk.com
Investors:
Kasper Roseeuw Poulsen	+45 3079 4303	krop@novonordisk.com
Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Melanie Raouzeos	+45 3075 3479	mrz@novonordisk.com
Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 71 / 2014